Better Health for All

Omnicell's core products, such as multimed blister packaging, have demonstrated exceptional health benefits by significantly improving medication adherence rates from 56% to 80-90% in one study, and from 61% to 97% in another.

This leads to better clinical outcomes, including improved blood pressure and lower HbA1c values, and reduces avoidable healthcare costs. The company's automated workflow technology also enhances patient safety and operational efficiencies in over 6,000 facilities and 40,000 pharmacies. There is no evidence of revenue from products with negative health outcomes. However, one adverse event report from 2021 noted three occurrences of dispensing discontinued medications, with one resulting in a potential incorrect dose administration, though no patient safety impact was identified. The company's solutions also contribute to preventative health by improving medication adherence, which is a key preventative measure. Additionally, Omnicell's technology is cited as improving clinician retention, addressing a significant challenge where 35-54% of clinicians experience burnout and 50% of pharmacy directors face staff shortages.

Fair Money & Economic Opportunity

Omnicell, Inc. is a healthcare technology company that provides medication management solutions to hospitals, health systems, and pharmacies.

Its core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer consumer credit products or financial services. The company's customers are institutional healthcare providers, not individual consumers seeking financial services. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility (for financial data), fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion (for financial access points), and product simplicity (for financial products), are not applicable to Omnicell's operations based on the provided evidence and the definition of the 'Fair Money & Economic Opportunity' value.

Fair Pay & Worker Respect

In 2024, Omnicell's CEO to median employee pay ratio was 79:1.

The company reported an employee satisfaction score of 73 in its OmniVoices survey for 2024, a five-point improvement from 2023. However, Omnicell did not achieve its goal of an 85% or greater employee retention rate in 2024 due to organizational restructurings. A lawsuit was filed against Omnicell by Larry L. Barnes for over $2 million in unpaid overtime, though the Tenth Circuit ruled against Barnes in May 2024, finding his on-call time did not qualify as "hours worked" under the FLSA. Workers receive employer-sponsored group health insurance, and executive officers receive health and dental insurance on the same basis as full-time non-executive employees. Approximately 92% of United States employees participated in the 401(k) plan in 2024.

Fair Trade & Ethical Sourcing

In 2024, Omnicell audited 35% of its Tier 1 suppliers, with a plan to audit 100% of Tier 1 suppliers over three years.

The company launched a Supplier Code of Conduct in 2024, which is now included in all supplier agreements and purchase orders. Its General Terms and Conditions of Purchase also include ethical clauses, and specific provisions in contracts for products supplied to California-based companies require suppliers to certify compliance with slavery and human trafficking laws. Omnicell follows OECD guidance for responsible sourcing of raw materials and conducted an on-site audit in 2023 and another in 2024 to assess conflict minerals reporting for in-scope suppliers. The company implemented Enhanced Supplier Screening in 2024 to continuously monitor supply chain risks, including labor rights, slavery, and human rights. Omnicell sets annual goals for allocating subcontracting dollars to diverse suppliers, including veteran-owned, service-disabled and veteran-owned, small, disadvantaged businesses, woman-owned, and HUBZone small businesses, and tracks performance on these goals annually.

Kind to Animals

No evidence was found in the provided articles to assess Omnicell, Inc. against any of the 'Kind to Animals' KPIs. The company's business description indicates it provides medication management and adherence solutions, including automated dispensing systems, software, and analytics tools. The articles provided discuss general industry trends in animal testing alternatives or focus on other companies' practices. Omnicell's own documents, such as its Anti-Trafficking Statement

, EHS Policy , and Code of Conduct , do not contain information related to animal welfare, animal testing, or animal-derived products. Therefore, no specific, concrete data points could be extracted for any of the KPIs.

Zero Waste & Sustainable Products

Omnicell has implemented a pilot take-back program for used Pods in Massachusetts and California, which includes instructions for customers on how to return them.

This program represents a waste reduction initiative for single-use disposable products. As part of this program, Pods are decontaminated before being sent for recycling or energy recovery, indicating proper hazardous waste management.